{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-22-297163","form_type":"8-K","ticker":"STOK","cik":"0001623526","company_name":"Stoke Therapeutics, Inc.","filed_at":"2022-12-02T23:59:59+00:00","discovered_at":"2026-05-14T18:03:51.474753+00:00","generated_at":"2026-06-21T10:16:46.722490+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Stoke Therapeutics reports 55% reduction in convulsive seizures in Phase 1/2a study of STK-001 in Dravet syndrome","bullets":["55% median reduction in convulsive seizure frequency from baseline in 6 patients treated with three doses of 45mg STK-001.","5/6 (83%) patients showed reductions; 4/6 (67%) had >50% reduction from baseline.","STK-001 up to 45mg well-tolerated; 27% (15/55) of patients had treatment-related AEs, all mild/moderate, no withdrawals.","Reductions in seizure frequency maintained in SWALLOWTAIL open-label extension; trend toward improvement in executive function (BRIEF-P).","One-year BUTTERFLY observational data showed little change in cognition without STK-001 treatment, highlighting disease progression."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-22-297163","json":"https://secwatch.observer/filing/0001193125-22-297163.json","markdown":"https://secwatch.observer/filing/0001193125-22-297163.md","text":"https://secwatch.observer/filing/0001193125-22-297163.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1623526/000119312522297163/0001193125-22-297163-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1623526/000119312522297163/d428421d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-21T10:16:46.722490+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}